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Sommario 
 La famiglia delle Protein Chinasi C è stata ampiamente studiata durante il 
differenziamento di diversi tipi cellulari. È noto che l'isoforma ε, appartenente al sottogruppo 
delle nuove PKC, esercita un essenziale  ruolo cardioprotettivo e di precondizionamento in 
seguito a danno da riperfusione. Inoltre, nel muscolo scheletrico adulto, la PKCε fa parte della 
via segnaletica che regola l'internalizzazione del glucosio in seguito alla contrazione 
muscolare. L'obiettivo di questa ricerca è stato quello di comprendere il ruolo fisiologico che 
la PKCε esercita durante il differenziamento muscolare cardiaco e scheletrico e di 
caratterizzare le vie segnaletiche coinvolte in questi processi. 
 Come modello di differenziamento cardiaco in vitro abbiamo scelto di utilizzare 
cellule staminali  mesenchimali del midollo osseo. I nostri risultati dimostrano che la PKCε 
regola negativamente l'espressione di due fattori di trascrizione essenziali per il 
differenziamento cardiaco, Gata4 e Nkx2.5 attraverso l'attivazione delle chinasi ERK1/2. 
 Abbiamo inoltre studiato il coinvolgimento della PKCε nel differenziamento 
muscolare scheletrico. Esperimenti effettuati in vitro dimostrano che la presenza nel nucleo 
della forma attiva di questa chinasi, fosforilata a livello della serina 729, inibisce la proteina di 
legame alla cromatina  HMGA1 e promuove l'espressione dei marcatori miogenici Miogenina 
e MRF4. Questa cascata molecolare promuove la fusione dei mioblasti e induce il 
differenziamento terminale scheletrico. Infine, abbiamo dimostrato che, in seguito a danno 
muscolare effettuato in vivo, la PKCε è espressa nelle miofibre rigeneranti centro-nucleate. 
L'utilizzo di un inibitore specifico della PKCε nel muscolo danneggiato inibisce l'espressione 
dei fattori di trascrizione miogenici MyoD e Miogenina, modulando negativamente il processo 
rigenerativo.  
 I nostri risultati dimostrano che la PKCε è un importante regolatore di geni essenziali 
coinvolti nel differenziamento muscolare scheletrico e cardiaco, suggerendo che l'espressione 
di questa chinasi deve essere finemente modulata in questi sistemi biologici. 
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Abstract 
Protein kinase C has been studied in the differentiation process of several cellular 
types. It is well-known that a novel isoform of this family, PKCε, exerts an essential cardio-
protective role and mediates the preconditioning in ischemia-reperfusion injury. Furthermore, 
in adult skeletal muscle, PKCε is involved in the signaling pathway that regulates glucose 
uptake after muscle contraction. The goal of this research was to elucidate the physiological 
role that PKCε plays during cardiac and skeletal muscle differentiation and to determine the 
molecular pathways involved in these processes.  
 We used rat bone marrow mesenchymal stem cells (BMMSCs) as a model of in vitro 
cardiomyogenic differentiation. Our results show the ability of PKCε to negatively regulate 
the expression of two essential cardiac transcription factors, Gata4 and Nkx2.5, via activation 
of ERK1/2. 
 We also studied the PKCε involvement in skeletal muscle differentiation. In vitro 
experiments reveal that the accumulation of phospho Ser729-PKCε in the nucleus inhibits of 
the chromatin binding protein HMGA1 and promotes the expression of the myogenic markers 
Myogenin and MRF4. This molecular cascade promotes in vitro myoblast fusion and 
myogenic terminal differentiation. We also found that, after in vivo muscle injury, PKC 
accumulates in regenerating, centrally-nucleated myofibers. In damaged muscle, PKC 
specific inhibition dramatically impairs the expression of the  myogenic transcription factors, 
MyoD and Myogenin, affecting the regenerative process. 
 Our findings  demonstrate that PKC is a critical regulator of essential genes 
involved in cardiac and skeletal muscle differentiation, suggesting that the expression of this 
kinase has to be finely tuned in these biological systems. 
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1.1 The heart 
1.1.1 Cardiogenesis  
 During gastrulation in mammalian organisms, cardiac precursor cells are in the 
splanchnic mesoderm, exactly in the lateral plate mesoderm. These cells, are responsible for 
the formation of the two heart-forming fields (Tam et al. 1997). The signaling pathway that 
regulates this process has been well studied. Eomesodermin, a T-box transcription factor, 
activates mesoderm posterior 1 (Mesp1) and induces the specification of splanchnic 
mesoderm into cardiac progenitor cells (Costello et al. 2011). Mesp1 regulates cardiac 
specification, up-regulating cardiac genes such as GATA4, Nkx2.5 and Mef2c (reviewed in 
Bondue and Blanpain 2010). External signals are also important in cardiac specification. The 
balance between positive regulators (Wnt and HegHog ligands, FGF and BMP)  secreted by 
endoderm and negative regulators (Wnt signaling) derived mainly from the neural plate, 
allows for a correct heart formation.   
 There are two populations of cardiac progenitor cells that act to generate the 
primitive heart. The first group of cardiac progenitor cells that differentiate  in the embryo are 
called primary heart field and are responsible for the formation of the atria and left ventricle. 
These precursor cells express Mesp1, Is11, Flk1, Mef2c and the transcription factors Nkx2.5 
and GATA4 (Moses et al. 2001; Yoon et al. 2006). After formation of the heart tube, derived 
from the folding of the lateral region of the anterior mesoderm toward the ventral midline, a 
second population of cells, called the secondary heart field, migrate to the growing heart. 
These cells give rise to the right ventricle, which include portions of the atria and the outflow 
tracks (Verzi et al. 2005; Kelly et al. 2001). However, these cells express both Flk1 and 
Nkx2.5 but not Isl1 (Cai et al. 2003). 
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 After a process of growth and remodeling, the heart tube loops to assume a structure  
that allows for the proper development and position of the future cardiac chambers. 
 
 
Figure 1.1 Developmental stages of Cardiogenesis (modified from Xei et al. (2013) Nat Rev 
Mol Cell Biol  14(8): 529-541)  
 
1.1.2 Cardiac regeneration 
 After birth, cardiomyocytes are mainly binucleated and contain a fully differentiated  
sarcomeric cytoskeleton.  The terminal differentiation of cardiomyocytes is preceded by cell 
cycle exit. In addition, the down-modulation of cell cycle effectors and the simultaneous up-
regulation of cell cycle inhibitors such as p21 and p27 was shown (Tane et al. 2014).  
 Growing evidence demonstrates that cardiomyocytes are also able to slowly self-
renew, thanks to a small pool of cardiac multipotent stem cells described for the first time in 
1998 by Anversa and Kajstura  (Anversa  and Kajstura 1998) and better characterized by 
Beltrami et al. in 2003 (Beltrami et al. 2003). These cells express the hematopoietic marker c-
kit, and are isolable and expandable ex vivo (D'Amario et al. 2011; Rota et al. 2008). Another 
important evidence about the heart's ability of self-renewal was given by Bergmann and 
coworkers. Thanks to the analysis of C
14
 in human hearts, they showed that at least 50% of 
cardiomyocytes are newly produced after birth, demonstrating that new cardiomyocytes are 
formed throughout adult life (Bergmann et al. 2009). 
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 To understand the contribution of proliferating cardiomyocytes and progenitor cells 
in the regeneration of injured heart, Malliaras and collegues used an engineered mouse line in 
which cardiomyocytes express GFP. After induction of myocardial infarction, the percentage 
of GFP
-
 cardiomyocytes increased, suggesting a big contribution of progenitor cells in cardiac 
regeneration (Malliaras et al. 2013). Furthermore, other studies show that a pool of preexisting 
cardiomyocytes reenter the cell cycle after injury, suggesting a role in the regeneration process 
(Senyo et al. 2013). The ability for cardiomyocytes to reenter the cell cycle seems to be related 
with morphological features such as the presence of a sarcomeric cytoskeleton or ploidy. 
Several groups demonstrated in different animal models and in the human that mononucleated 
cardiomyocytes are more prone to reenter the cell cycle than binucleated cells, the major 
population  present in an adult heart (Mollova et al.  2013; Bersell et al. 2009). 
 Bone marrow-derived mesenchymal stem cells (BMMSCs) are one of the most non-
cardiac adult stem cell type studied in cardiac regeneration, thanks to their ability to 
differentiate into cardiomyocyte-like cells  (Makino et al. 1999).  
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Table 1.1 The studies addressing the transdifferentiation of Bone Marrow cells into cardiac 
cells ( modified from Antioxid Redox Signal. 2009 Kim et al. (8):1897-911)  
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 Several protocols and different stimuli that induce MSCs cardiomyogenic 
differentiation are known. A characterized medium containing insulin, transferrin, 
dexamethasone, ascorbate phosphate, linoleic acid, and sodium selenite is able to induce 
cardiomyocytic differentiation in MSCs cultured in vitro. These cardiomyocyte-like cells 
express several cardiac markers like TnI, connexin-43, and β MHC and are negative for 
specific skeletal markers such as MyoD (Shim et al. 2004). 
 5-azacytidine is a cytosine analog, able to induce DNA demethylation and in vitro 
cardiac differentiation of MSCs. The upregulation of cardiomyocyte genes after 5-azacytine 
induction is due in part to demethylation of the glycogen synthase kinase (GSK)-3 promoter 
and its transcription activation (Yang et al. 2009). 
 The co-culture of MSCs with neonatal cardiomyocytes induce the stem cells 
differentiation in cardiomyocyte-like cells that are able to beat synchronously. Evidences in 
vivo show that exogenous MSCs and endogenous cardiomyocytes cooperate during 
regeneration after myocardial infarction (Hatzistergos et al. 2010). Another group also 
demonstrated the regenerative effects of human MSCs and c-kit
+ 
cardiomyocytes on the 
anatomical and functional characteristics of the infarcted heart (Williams et al. 2013). 
 
1.1.3 GATA Family 
 
 The mammalian GATA family consists in six isoforms of zinc finger transcription 
factors that have an important role in the regulation of cell differentiation in several tissues 
and cell types. All GATA isoforms share a common structure, in which transcriptional 
activation domains are localized in the N-terminal region and two zinc fingers allow the 
interaction with DNA. These proteins have also a nuclear localization signal sequence (NLS) 
that guide their nuclear translocation. The DNA binding domains recognize the consensus 
sequence (A/T)GATA(A/G) (Morrisey et al. 1997a) and regulate the transcriptional control of 
target genes. 
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Figure 1.2  Panel A: General structure of mammalian GATA family. (AD) Activation 
domain; (ZN) Zinc fingers domains; (BR) Basic regions; (NLS) Nuclear Localization Signal; 
(CTD) C-terminal domain. Panel B: Schematic structure of a GATA zinc finger (Boaz et al., 
American Journal of Physiology - Gastrointestinal and Liver Physiology (2014) 306(6), G474-
G490 
 
 Thanks to the analysis of sequence homology and function, these proteins have been 
classified in two subgroups. The first, formed by GATA1, GATA2 and GATA3, is expressed 
mainly in the hematopoietic system, which play important roles in cell specification and 
development (reviewed by Orkin, 1992 and Weiss, 1995). GATA4, GATA5 and GATA6, 
belonging to the second subgroup, are well known for its implication in endoderm 
development during embryogenesis. They are mainly expressed in the heart, liver, pancreas, 
lung, gonad, and gut (reviewed in Molkentin, 2000a), which control the expression of specific 
gene subsets. 
 During heart development and cardiomyocyte differentiation, GATA transcription 
factors are highly expressed and show an important role in cardiogenesis.  
 Two independent groups have studied GATA4 null mice demonstrating that this 
transcription factor is required during heart development to form the primitive heart tube (Kuo 
et al. 1997; Molkentin et al. 1997). The mechanism proposed is that GATA4
-/- 
mice develop a 
splanchnic mesoderm in which there are primitive cardiomyocytes, but these cells are not able 
to migrate in the ventral midline and form the heart tube. These studies suggest that GATA4 
expression is required for migration of procardiomyocytes in the embryo and for correct 
morphogenesis of the primitive heart, but is not essential for cardiac-cell specification. This 
theory is supported by other evidence that show the importance of GATA4 in cardiac 
precursor cell survival, but not for cardiac commitment of these cells (Grépin et al. 1997). 
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During mouse embryogenesis, GATA5 is expressed in the developing heart, first in the 
precardiac mesoderm and then in the atrial and ventricular chambers but is not detectable in 
late fetal and post natal heart development (Morrisey et al. 1997b). However, the role of this 
gene in heart development is not well explained in GATA5
-/-
 mice, in which there are no 
evident abnormalities in heart formation, suggesting a redundant effect of other GATA factors 
in this system (Molkentin et al., 2000b). 
 Finally, GATA6 knock out is lethal in the early stage of embryonic development, 
before heart formation. Further studies on Xenopus and Zebrafish embryos using a RNA 
interfering approach demonstrated the role of this transcription factor in maturation and 
maintenance of cardiac progenitor cells by over-expression of Bone Morphogenetic Protein 4 
(BMP-4) and Nkx2 family members (Peterkin et al. 2003). 
 
1.1.4  Nkx 2.5 transcription factor 
 
The NK family members are four homeobox transcription factors classified into two 
homeodomain protein subgroups (NK1 and NK2- NK4).  
 
Fig. 1.3.   General structure of vertebrate NK2 proteins. ( Akazawa and Komuro. (2005) 
Pharmacology & Therapeutics 107 252 – 268) 
 
 Nkx 2.5 is a cardiac transcription factor involved in heart development and post-natal 
cardiomyocyte gene regulation. In human, mutations of this gene were found in patients 
affected by congenital heart diseases (Schott et al. 1998) or congenital bicuspid aortic valve 
(Yuan et al. 2015). 
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 Nkx 2.5  (the fifth gene identified in the NK2 subgroup) is formed by a TN domain, a 
NK2-SD domain and a homeobox domain that interacts with DNA through a helix-turn-helix 
DNA-binding motif and recognize the DNA sequence 5’T(C/T)AAGTG3’ (Chen and 
Schwartz, 1995). 
 During embryogenesis, Nkx2.5 is expressed in both heart fields, suggesting an 
important role of this transcription factor in the cardiac transcription program during 
cardiogenesis. At least three different Nkx2.5-deficient mice models were generated and all 
showed defects on heart tube morphogenesis that are incompatible with life (Lyons et al., 
1995; Tanaka et al., 1999a; Biben et al.,2000). Other transgenic mice, in which Nkx2.5 
mutation is inducible and restricted only in ventricular cardiomyocytes, have permitted to 
study the involvement of this gene in ventricular cardiomyocyte specification (Pashmforoush 
et al. 2004). These mice display a normal morphogenesis of heart structure but are subject to 
heart failure due to chamber dilatation and hypertrabeculation. 
 Nkx2.5 activity is also important for the specification and proliferation control of the 
conduction system in a dose-dependent matter. Indeed, an elegant experiment of Jay and 
colleagues demonstrate that the Nkx 2.5 mutant lacks the formation of a functional conduction 
system, but Nkx 2.5 haploinsufficient mice display half of the normal number of functional 
Purkinje cells (Jay et al. 2004). 
 The transcriptional activation of the Nkx2.5 gene is hard to completely understand 
because of the complexity of its upstream regulatory region. The most studied complex that 
regulates Nkx2.5 expression during heart cardiogenesis is the Smad1/4-GATA4/6 complex. 
This proteins bind a ~200bp DNA sequence upstream of the Nkx2.5 gene in which are present 
several binding sites for GATA and SMAD are present. SMAD and GATA act in this system 
like mutually interacting cofactors that enhance the recruitment and the binding of the other 
proteins to their sites. (Brown III et al, 2004). Interestingly, Smad proteins are trasducers of 
bone morphogenetic protein (BMP) signaling, which is known to activated Nkx2.5 
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transcription and cardiac differentiation in P19CL6 murine embryonal carcinoma cells 
(Monzen et al., 1999).  
Finally, Nkx2.5 drives the expression of essential structural proteins and transcription factors 
during cardiac differentiation such as ANP, cardiac α-actin, A1 adenosine receptor, connexin 
40, calreticulin, myocardin, MEF2-C and other, reviewed by Akazawa and Komuro, (2005).  
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1.2 Skeletal muscle differentiation 
1.2.1 Embryonic development of skeletal muscle 
 The embryonic development of skeletal muscle is spatially and temporally regulated 
and allows for the formation of differentiated and functional muscles. In vertebrates, skeletal 
muscle cells arise from the mesoderm, in the middle layer of the embryo. Trunk and head 
muscles derive from cells located in different positions. The trunk and limb muscles derive 
from somites, cells that are located in the segmented paraxial mesoderm. These cells form the 
dermomyotome in the dorsal part of the neural tube, the sclerotome in the ventral part and the 
myotome, a product of delamination of Myf5
+
 cells underneath the dermomyotome. In the 
myotome take place the first event of myogenesis, followed by a second event of 
differentiation driven by fetal myoblasts that are derived from all four lips of the 
dermomyotome (Duxon et al. 1989). 
 
Figure 1.4 Panel A: Schematic representation of a 13 somite amniote embryo ( ~24 days 
stage in human, E8.5 in mouse) and the location of myogenic regions. Panel B: Illustration of 
the transverse section of an embryo. The mesodermal derivates are in blue, the ectodermal 
derivates are in orange and the endoderm is in yellow. Panel C: Spatial organization of 
somites, the dermomiotome is in red, the myotome is in  green and the sclerotome is 
represented in blue. Panel D: Immunostaining of Pax 3 and MF20 (sarcomeric myosin) in a 
trasverse section of a chicken embryo. (Mok and Sweetman, Reproduction (2011) 141 301–
312) 
 
 The head muscles have a completely different origin. Head muscles derive from the 
cranial paraxial mesoderm and the lateral splanchnic mesoderm. The muscle formation 
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process starts with the progressive differentiation of  pluripotent cells, thanks to a complex 
interplay of soluble factors and transcription factors that result in the formation of functionally 
specialized cells.  
 It is known that the differentiation of pluripotent stem cells  to form the specialized 
skeletal muscle tissue is driven by a network of transcription factors that mainly comprise 
myogenic regulatory factors (MRFs) and other factors like PAX3 and PAX7. Pax3 and Pax7 
are transcription factors expressed in the cells of dermomyotome. Pax3 is known to be 
essential during embryonic myogenesis (Bober et al. 1994) and Pax7 is mostly required during 
postnatal myogenesis (Oustanina et al. 2004).  
 The myogenic regulatory factors (Myf5, MyoD, Mrf4 and MyoG) are basic helix–
loop–helix transcription factors that bind to the E-box sequence CANNTG and regulate the 
differentiation of skeletal muscle cells. The myogenic regulatory factors (MRFs) initiate the 
transcriptional cascade that sustainS the skeletal muscle terminal differentiation during 
embryronic development and in postnatal life. Myf5 is a determination factor; embrionic cells 
with the double knockout Myf5
-/-
:MyoD
-/-
 fail to
 
develop skeletal muscle (Rudnickiet al. 
1993), suggesting that MyoD and Myf5 are determination factors that are hierarchically 
upstream of myogenin and MRF4.  
 The Myogenin knockout shows perinatal death due to a total absence of functional 
skeletal muscle. (Hasty et al. 1993; Nabeshima et al, 1993) These studies suggest that MyoG 
is a regulator of late myogenesis. 
  Skeletal muscle development ends during postnatal life, when satellite cells 
differentiate and fuse with growing myotubes. Few cells remain in a quiescent state and 
establish the pool of resident stem cells in the adult muscle. 
 
1.2.2 Satellite cells and skeletal muscle regeneration 
 Although skeletal muscle regeneration appears to be related with different muscle-
derived populations, it is mainly sustained by resident stem cells called satellite cells 
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(Mauro,1961).  These mononuclear cells are localized underneath the basal lamina of muscle 
fibers and represent ~ 2-6% of all nuclei in healthy mammalian muscle fiber.   
 
Figure 1.5  Panel A: Adult mouse myofiber stained with anti Pax7 antibodies (Red) and 4′,6-
diamidino-2-phenylindole (Blue). Panel B: Schematic illustration of the picture showed in 
Panel A. (Yablonka-Reuveni et al. J ANIM SCI 2008, 86:E207-E216.) 
 
 After stimulation by specific factors, satellite cells start to proliferate and differentiate 
to form new myofibers. At the same time, a subset return in a quiescent status and replenish 
the satellite pool of dormant stem cells in the muscle (Abou-Khalil et al 2010). The major 
signaling pathways implicated in the quiescence of satellite cells are the Ang1 /Tie2 signaling 
pathway(Abou-Khalil et al. 2009), the P38/MAPK pathway (Jones NC et al 2005) and 
Myostatin via regulation of Pax7 expression (McFarlane et al. 2008). 
 The staminality of satellite cells was proved by different groups. Collins et al., in 
2005, described an engrafting procedure that allowed to transplant  a single myofiber in which 
the satellite cells were tracked with a nuclear Myf5-lacZ reporter. This experiment definitely 
proved stem cell activity of satellite cells and their ability of self-renewal. (Collins et al. 2005)  
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More recently, another group showed that satellite cells are able to conserve their stem cell 
ability after more than seven rounds of serial transplantation (Rocheteau et al. 2012.) 
 Another fundamental characteristic of stem cells is the ability to undergo asymmetric 
cell division, giving rise to two different cells, one able to proliferate and the second that 
remains in the stem cell pool in a quiescent status.  Studies on satellite cells reveal that protein 
like Numb, the Notch inhibitory protein, and MyoD are asymmetrically segregated in 
daughter cells during cell division. (Conboy et al. 2005; Zammit et al. 2004)  
 The Paired Box 7 (Pax7) transcription factor is a common marker of quiescent 
satellite cells. On the other hand, the expression of Pax3 is a characteristic of few specific 
muscles such as the diaphragm (Relaix F et al.2006). Quiescent cells also express Myf5 but 
not MyoD. After activation, satellite cells lack the expression of Pax7 and produce Myf5 and 
MyoD, followed by Myogenin and MRF4. 
 To study the regenerative property of satellite cells, several different models such as 
crush, freeze, or chemical injuries have been proposed.  One of the most popular and 
reproducible methods used to induce the activation of  the myogenic regenerative program 
after injury is the intramuscular injection of cardiotoxin or other chemical agents. After injury, 
the ordinate muscular structure appears disrupted and an interstitial neutrophillic infiltration is 
detectable. The presence of inflammatory cells in this phase allow for the phagocytosis of 
necrotic fibers. The activation and proliferation of satellite cells is followed by differentiation 
in myotube and fusion with preexisting myofibers or toghether to form new growing 
centronucleated myofibers (Goetsch et al. 2003). 
 Under pathological conditions, such as dystrophies or aging, satellite cells fail to 
complete the regenerative process, leading to fibrosis and fatty infiltration in the damaged 
muscle.   
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Figure 1.6 Muscle regeneration after injury. Panel A: Schematic representation of satellite 
cell activity during regeneration. Panel B: Hematoxylin - eosin staining of a disrupted muscle 
after cardiotoxin - induced injury. The arrow indicates a centronucleated growing myofiber. 
Panel C: Hematoxylin - eosin staining after 2 weeks of injury. The morphological structure of 
the muscle is restored. The arrow indicates a mature myofiber in which the nucleus is in a 
pheripheral position. (Shi and Garry, Genes Dev. 2006 20: 1692-1708) 
 
1.2.3 HMGA family 
 Chromatin is the structure in which DNA is organized into the nucleus of eukaryotic 
cells and its structural and functional units are nucleosomes. To allow for gene transcription, 
chromatin must interact and bind to transcription factors  and other DNA binding proteins. 
The organization of chromatin structure is one of the most important functions of non-histone 
proteins and the most numerous group is represented by the High Mobility Group (HMG) 
family.  
 These proteins are "architectural factors" grouped in three different families based on 
their different DNA binding domain. Although these three groups have similar functions, each 
family maintains a typical  way to interact and  modulate chromatin structure.  
 The HMGA group is characterized for the presence of an AT-hook DNA-binding 
domain. This palindromic motif binds preferentially to the minor groove of DNA in A/T rich 
sequences (Reeves and Nissen, 1990). 
16 
 
 HMGB proteins contain the HMG- boxes structure, two tandem DNA-binding 
regions that bind the minor groove of the DNA with low sequence specificity followed by an 
unstructured acidic tail. Finally, the six HMGN proteins (HMGN1, HMGN2, HMGN3a, 
HMGN3b, HMGN4 and HMGN5) contain a nucleosomal binding domain, and an acidic tail 
called the chromatin-unfolding domain (Bustin, 2001). 
 
Figure 1.7. Structure of HMG family members. ( Katex and Hock Biochimica et Biophysica 
Acta 1799 (2010) 15–27) 
 
 The major role of HMG proteins is to modulate chromatin structure allowing for the 
binding of other proteins to the DNA and the transcription of specific genes. (Reeves, 2010).  
In mammals there are four components of the HMGA subfamily (HMGA1a, HMGA1b, 
HMGA1c, and HMGA2), encoded by two distinct genes, Hmga1 and Hmga2. HMGA1a, 
HMGA1b and HMGA1c derive by alternative splicing from the Hmga1 gene  and Hmga2 is 
encoded by its own gene. These proteins, with the rare exception of HMGA1 contain three 
AT-hook DNA binding motifs.  
 HMGA proteins are able to modify chromatin condensation affecting the nucleosome 
structure near the target genes, or changing the conformation of more domains at the same 
time. The discovery of specific HMGA binding sites in the chromatin structure of metaphase 
chromosomes (Disney et al., 1989) suggests that these proteins are involved in the 
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chromosomal changes that  occur during the cell cycle. For example, during the G2/M 
transition, HMGA1 proteins are phosphorylated by cdc2 kinase, decreasing their ability to link 
DNA (Reeves et al., 1991).  HMGA proteins are also able to compete with Histone 1 (H1) for 
binding to Scaffold Attachment Regions (SARs), which are A/T-rich sequences constitutive of 
metaphase chromosomes. The competitive binding with SARs of H1 or HMGA proteins is 
able to modulate chromatin condensation and structure. (Zhao et al., 1993). 
 HMGA proteins coordinates the formation of the enhanceosomes, multi-subunit 
complexes that link to A/T-rich promoter regions of specific genes, thus enhancing their 
transcription. ( Merika and Thanos, 2001). One of the most characterized mechanisms in 
which HMGA1 can  promote transcription via the induction of enhanceosome formation  is 
the production of IFN-β after viral infection. HMGA1 coordinates the assembly of the 
enhanceosome on an A/T-rich sequence near the IFN-β promoter, inducing the transcription of 
this important gene involved in the innate immune response (Dragan et al. 2008). 
 Another well characterized mechanism is explained by the study of IL-2 and CRYAB 
gene transcription. In activated T lymphocytes, HMGA1 is involved in the transcription 
process of IL-2 and IL-2 α (Himes et al. 1996; John et al. 1995), allowing the formation of the 
enhanceosome and the transcription initiation of both of these genes (John et al. 1996). 
HMGA also activates the alpha-B- crystallin (CRYAB) gene transcription, allowing for the 
production of the CRYAB heatshock protein. The mechanism comprises the binding to 
HMGA1 on a response element located near an inhibitory nucleosome and the further 
recruitment of the transcriptional factors BRG-1 and AP-1 on the gene promoter (Duncan and 
Zhao, 2007). In both of these cases, HMGA1 allows for the destruction of inhibitory 
nucleosomes, showing regulatory DNA elements essentials for the binding of key 
transcriptional factors. 
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1.3 Protein Kinase C family 
 The PKC superfamily, belonging to the AGC family of kinases, consists of at least 11 
serine/threonine kinase isoforms. They are mainly regulated by calcium (Ca
2+
) and 
diacilglicerol (DAG), but also by lipids like phosphatidylserine (PS) and sphingolipids. PKCs 
are subdivided into three classes, grouped according to their structure and modality of 
activation. The classic or conventional PKCs (cPKCs) (PKCα, PKCβI, PKCβII and PKCγ) are 
activated by Ca
2+
, DAG and PS. However, the novel PKCs (nPKCs) (PKCδ, PKCθ, 
PKCε,PKCµ and PKCη) are Ca2+ independent and regulated by DAG and lipids, whereas the 
atypical PKCs (PKCζ and PKCί/λ) are both Ca2+ and DAG independent (Reviewed by Rosse 
et al. 2010). 
 
Figure 1.8.  Structure of PKC family members ( Wu-Zang and Newton, Biochem J. (2013) 
452(2): 195–209.) 
  
Most of these kinases are widely expressed in mammalian tissues, with the exception of PKCγ 
that is typical of the nervous system (Hughes et al. 2008) and the PKCη that is found 
predominantly in epithelia (Suzuki et al. 2009). 
 The common structure of PKCs includes a N-terminal regulatory domain and a 
highly conserved C-terminal catalytic domain separated by a hinge region.   
 cPKCs possess two tandem membrane-targeting domains: C1A and C1B bind DAG 
and phorbol esters in membranes and the C2 domain binds membranes in the 
presence of the second messenger Ca
2+
. 
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 nPKCs contain two tandem C1 domains with a 100-fold higher affinity for DAG than 
the C1B domain of cPKCs (Giorgione et al. 2006). They also possess a novel C2 
domain that does not bind the second messenger Ca
2+
 . 
 aPKCs possess a C1B domain that allows them to bind anionic phospholipids and a 
PB1 domain that mediates protein-protein interactions. 
All these isoenzymes have a short autoinhibitory pseudosubstrate sequence in the regulatory 
domain. When this sequence occupies the substrate-binding pocket, it maintains PKC in an 
inactive conformation. Binding of second messengers in the regulatory domain induces a 
conformational modification that allows for the pseudosubstrate release and activation of the 
active site (Dutil and Newton 2000) 
 The catalytic domain contains an ATP-binding site and a substrate binding site. To be 
catalytically competent, PKCs need to be phosphorylated in three different sites in the 
catalytic domain. These sites are in the activation loop, in the turn motif and in the 
hydrophobic motif. 
Targets of PKCs show a phosporylation site (Serine or Threonine) surrounded by a basic 
amino acid at N-terminal -2 or -3 position and a hydrophobic amino acid at C-teminal +1 
position. Studying these characteristics, many consensus phosphorylation sites for PKCs are 
known. The most common are (R/K)X(S/T), (R/K)(R/K)X(S/T), (R/K)XX(S/T), 
(R/K)X(S/T)(R/K, and (R/K)XX(S/T)XR/K (Nishikawa et al. 1997). 
 In physiological conditions, PLC - PIP2 - DAG is the major pathway of PKC's 
activation. The α-adrenergic receptors activate phospholipase C (PLC) via Gq proteins. This 
pathway involves the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2), generating 
inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG), the major physiologic activator of 
PKC.  
 A mechanism of self-inhibition of PKC activity is the interaction of the 
pseudosubstrate sequence with the substrate-binding motif of the catalytic domain that leads 
to the inability to link and phosphorilate substrates (Orr and Newton, 1994). Binding of 
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activators like DAG and PMA on the regulatory domain causes a conformational change that 
release the active site from the inhibition of the pseudosubstrate motif and activates PKCs.  
PKCs are also sensitive to cleavage by proteolytic enzymes like calpain or caspases in the 
hinge region. The final products are usually constitutively active, even in the absence of 
second messengers  (Kishimoto, 1989). 
 Regulation of PKCs activity occurs also via interaction with transporters and other 
proteins. The most characterized are Receptors for Activated C Kinases (RACKs), A-Kinase 
Anchoring Proteins (AKAPs) and 14-3-3 proteins. RACKs are intracellular PKC receptors 
that interact with the regulatory domain of PKCc and are responsible for their subcellular 
localization. Their function is critical for PKCs activation,  interaction with substrates, and 
cellular responses. 
 Since the PKC family was discovered, it has been a goal to develop specific 
molecules capable to modulate the function of these kinases in an isoform specific manner. 
The high sequence homology between the different groups and isoforms has made this goal 
difficult to achieve. Different approaches were tried, including the development of active site 
inhibitors, which are small molecules that activate or inhibit PKC mimicking the binding of 
DAG, the physiological activator of the classical and novel PKC, and peptides that act 
disrupting the protein-protein interaction.  
 The active site inhibitors, are small molecules that compete with ATP to bind to the 
ATP-binding site. These type of inhibitors are efficient in activating PKC but have low 
specificity, because the ATP binding pocket is a well conserved region of these proteins and it 
shows high sequence homology not only  between different isozymes but also with other 
serine/threonine kinases.  The best characterized is the bisindolylmaleimide family. They are 
water soluble compounds, isoenzyme-non-specific PKC inhibitors that act on all three classes 
of PKC isoenzymes in vitro, but are more effective against conventional and novel PKCs than 
atypical isoenzymes. They do not inhibit the closely related PKA or PKD but are highly 
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effective against other kinases like FLT3, GSK3, GSK3β, PIM1, PIM3 and RSK1–RSK4 
(Anastassiadis et al. 2011). 
 The non-active site activators/inhibitors are molecules that target the regulatory 
domains of these enzymes. A well-characterized family mimics the binding of DAG - the 
physiological activator of classical and novel PKCs - to the C1 domain. Examples of 
activators are the phorbol esters, that cause an irreversible activation of  PKCs 
(Blumberg1980) or diacylglycerol-lactones. Modified diacylgliycerols show higher affinity 
for the PKC's C1 domain than the natural counterpart. (Marquez et al., 1999). 
A new class of PKC inhibitors is composed by small peptides that are able to interfere with 
PKC interaction with specific transporters, crucial for their translocation and subcellular 
localization. The peptide inhibitors are competitive antagonists that have the same sequence 
and structure of the PKC's C2 domain and compete with the native kinase to the binding with 
RACK. This results in the inhibition of translocation and phosphorylation of the substrate. 
Instead, the peptide shows sequence homology with the PKC pseudo-RACK site and binds 
PKC, thus stabilizing the active conformation of the protein. Interestingly, RACK has a higher 
affinity than the activator and it is able to bind the activated PKC and mediate the 
translocation. (Churchill et al. 2009) 
 
1.3.1 Protein Kinase C ε  (PKCε) 
 PKCε is a novel isoform characterized by wide expression in many tissues and organs 
and with well known activity in the cardiac (Budas and Mochly-Rosen, 2007), nervous (Shirai 
2008) and immune system (Aksoy, 2004) as well as in cancer development.   
 Commonly with the other classical and novel PKC isoforms, three major sites of 
phosphorylation were identified in the C-terminus of PKCε. In the Activation-loop, 
phosphorylation of Thr566 is necessary for catalysis because it induces conformational 
modifications that stabilize the active conformation of this kinase. The most characterized 
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kinase that catalyses this phosphorilation is the Phosphoinositide- Dependent Protein Kinase-1 
(PDK1).  
Studies in vitro have revealed that the over-expression of PDK1 increases PKCε Thr566, 
Interestingly, this first phosphorilation event triggers autophosphorilation of the Ser729, 
located in the hydrophobic motif (Cenni et al. 2002).  Also PDK1 down-modulation has 
important effects on PKCε phosphorilation and activity. Balendran et al. shown that murine 
PDK1
-/- 
embryonic stem cells have low levels of PKCε including other novel and conventional 
PKCs, suggesting that phosphorilation in the activation loop could also have a role in the 
stabilization of this protein. (Balendran et al. 2000). However, more recent studies on other 
related PKCs suggest that PDK1 is not the only kinase that can phosphorilate this site. Ser729 
is a target of the mTORC1 complex and the treatment with rapamycin, a mTORC1 inhibitor, 
can affect the PKCε phosphorilation in this site (Parekh D,1999). Other possible sites of 
phosphorilation are Ser-234, Ser-316, and Ser-368. Little is known about the functional effects 
of this phosphorilation, but they are probably targets of conventional PKC or auto-
phosphorilation sites (Durganet al. 2008).  
 After activation, PKCε translocates to membranes or other subcellular compartments, 
thanks to the anchoring proteins Receptor for Activated C-Kinase1 and  2 (RACK1 and 
RACK2). Specifically, RACK2 allows the active phospho - Ser
729 
kinase to translocate to the 
Golgi membrane. 
 The role and function of PKCε in several tissues has been investigated.  In the 
nervous system, PKCε is the most abundant PKC and has various effects in this system. 
Interestingly, several studies conducted in murine animal models show that this kinase is able 
to modulate the sensibility of GABAA receptors and up-regulate the expression of N-type 
channels  inducing alcohol dependency (Besheer et al. 2006).  Moreover, activation of PKCε 
led to an improvement of the functionality of neuronal cells in Alzheimer's disease that 
correlates with a reduction of β-amyloid protein levels. (Nelson et al. 2009). In the colon, the 
down-modulation of  PKCε is required for TRAIL and butyrate induction of colonic epithelial 
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cell differentiation (Gobbi G et al. 2012). In the hematopoietic system, PKCε is needed to 
protect erythrocytes and acute myeloid leukemia against apoptosis (Gobbi G et al. 2009; 
Mirandola P et al. 2006). PKCε's role and its fine regulation in  megakaryocytic differentiation 
is also well documented (Gobbi G et al. 2007; Gobbi G et al. 2013).  
In skeletal muscle, high levels of PKCε are able to modulate the expression and sensitivity of 
the Insulin Receptor (IR) causing insulin resistance (Dey et al. 2007). During muscle 
contraction, PKCε promotes glucose uptake through the modulation of GLUT4 traffic (Niu et 
al., 2011). Less is known about the involvement of PKCs in muscle differentiation.  PKCθ 
isoform principally regulates the fusion process, modulating the expression of caveolin-3 and 
β1D integrin (Madaro L et al., 2011). The same group has published conflicting data, 
demostrating that the deletion of PKCθ in an animal model of muscular dystrophy improves 
muscle regeneration. The possible explanation for this phenotype is that PKCθ is a potent 
inflammatory promoter and in its absence the exaggerated inflammatory response  in damaged 
and pathologic muscle is reduced (Madaro et al. 2012). Finally, PKCε mRNA and protein 
expression increases during insulin-induced myogenic differentiation of the C2C12 cell line 
(Gaboardi GC et al., 2010).  
 In the heart, PKCε has well known cardioprotective effects and mediates the 
preconditioning in ischemia-reperfusion injury.  Studies performed in vivo with peptic 
activators show that pretreatment with the activator peptide before heart ischemia results in a 
strong cardioprotective effect (Inagaki et al. 2005). One of the mechanisms proposed is that 
activation of PKCε after short-term periods of ischemia leads to a positive regulation of 
mitochondrial Aldehyde Dehydrogenase 2 (ALD2) and a consequent decrease of damage in 
the heart. (Dorn et al. 1999; Chen et al. 2008). PKCε is also able to increase sarcKATP channel 
activity after preconditioning, leading to ATP preservation and a reduction of Ca
2+
 entry. 
(Aizawa et al. 2004). Finally connexin43, a well known component of cardiomyocyte Gap 
junctions, is a direct target of PKCε in human and rat cardiomyocytes (Doble et al., 2000; 
Bowling et al., 2001). 
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 Although the role of the PKCε pathway has been extensively studied in cardiac 
preconditioning and in the adult heart (Inagaki et al. 2005: Dorn et al. 1999; Chen et al. 2008), 
little is known about its implication in cardiac differentiation. 
The role of PKCε in skeletal muscle differentiation is also less clear. Only a precedent study 
suggests that  PKCε is up-regulated during insulin-induced myogenic differentiation of the 
C2C12 cell line (Gaboardi et al., 2010).  
The goal of the present study was to evaluate the PKCε pathway during cardiac and skeletal 
muscle differentiation. In particular my interest has been focused on the BMMSCs cardiac 
differentiation induced by 5-azacytine treatment and murine C2C12 myoblast and primary 
satellite cells ex vivo.  
 
 The first aim was to understand a possible connection between PKCε and the 
cardimyocyte transcription factors Nkx2.5 and GATA4, two well known markers of 
early cardiac differentiation. 
 
 The second aim was to understand  the PKCε pathway in skeletal muscle 
differentiation  in vitro and ex vivo and explain the possible  interconnection between 
PKCε and the chromatin binding protein HMGA1 signaling. 
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3.1 Mice 
All animal experiments described in this thesis were approved by the Local Animal 
Research Ethics Committee. In addition, the experimental procedures were conducted 
according to the “Guide for the Care and Use of Laboratory Animals” (Directive 2010/63/EU 
of the European Parliament). 
 
3.2 Cell cultures 
 Bone Marrow Mesenchymal Stem Cells (BMMSCs) were isolated from Wistar rats' 
bone marrow after euthanization with overdoses of pentobarbital. Tibia and femurs were 
collected  in aseptic conditions and cleaned from muscles and other soft adherent tissues. 
After excision of the proximal and distal ends, the marrow plugs were flushed from the bone 
marrow cavity and collected in  Dulbecco’s modified eagle’s medium (DMEM) supplemented 
with 10 % Fetal Bovine Serum (FBS). To isolate BMMSCs, Percoll media (density 1.13 g/ml) 
was used to isolate mononuclear cells by density centrifugation. The mononuclear fraction 
was grown in low glucose DMEM with 10% FBS in a humidified 5% CO2 atmosphere at 
37°C and non-adherent cells were removed after 24 h. BMMSCs were then induced to 
differentiate in different cell types: 
 Cardiac differentiation was induced by treatment with 10 μM 5-azacytidine (Sigma-
Aldrich, Milan, Italy) for 24 h. Cells were then cultured in a differentiation media 
(DMEM low glucose, 2 % horse serum) for up to 30 days. In order to inhibit the 
ERK pathway, cardiomyocytes-like cells were pre-treated with 10 μM of the 
MEK1/2 inhibitor U0126 (Cell Signaling, Boston, USA) for 30 min before cell 
transfection. 
 Osteogenic and adipogenic differentiation were induced by treatment with specific 
media from Stem Cell Technologies (Vancouver, Canada) and verified by Alizarin 
red and Oil red Oil staining, respectively. 
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Satellite cells (SCs) were isolated from hindlimb muscles of neonatal (2 days old) 
CD1 mice. Muscles were minced and then incubated with a collagenase/dispase solution 
(Roche, Basel, Switzerland) for a total of 4 digestions. Cell suspension was filtered with 40 
µm nylon cell strainer and stained with the Feeder Removal Microbeads kit (Miltenyi Biotec, 
Bergisch Gladbach, Germany) and immunomagnetic separated following the manufacturer’s 
instructions. Fibroblast negative fraction was seeded at a density of 1.25 x 10
5
/cm
2 
in 
collagen-coated culture dishes. Non-adherent cells were removed after 24 h and satellite cells  
were grown in a fibroblast-conditioned medium obtained by mixing (1:1 ratio) Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with heat-inactivated 10% fetal bovine 
serum (FBS) (Growth Medium, GM) with filtered supernatant of primary cultures of mouse 
fibroblasts grown in GM. Mouse myoblast C2C12 cell line and primary SC were cultured in a 
humidified 5% CO2 atmosphere at 37°C. To induce myogenic differentiation, when the cell 
cultures reached 80% confluence the GM was substituted with DMEM supplemented with 2% 
horse serum (Differentiation Medium, DM).  
 
3.3 RNA extraction and quantitative RT-PCR  
 Total RNA was extracted using Trizol reagent or the RNeasy mini kit (Qiagen) 
according to the manufacturer’s instructions. 1 μg of total RNA was reverse transcribed using 
ImProm-II™ Reverse Transcription System (Promega, Fitchburg, WI) in a final volume of 20 
μl. Quantitative real-time PCR assay was performed on 2μl of the 1:5 dilution of cDNA using 
Syber Green method. Polymerase chain reactions were made by StepOne Real-Time PCR 
System (Applied Biosystems) and GoTaq ® qPCR Master Mix (Promega). For each well, the 
20 μl reaction medium contained: 10 μl of 2X GoTaq ® qPCR Master Mix (with SYBR 
Green), 100 nM each forward and reverse primer, 7,6 μl of RNase-free water and 2 μl cDNA 
template 1:5. The cycling conditions were: 95°C for 20s followed by 40 cycles of 95°C for 3s 
and 60°C for 30s. Real-Time RT-PCR products were confirmed by the analysis of melting 
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curves. The amount of the target transcript was related to that of the reference gusb gene by 
the method of Comparative CT.  
The sequence of primers used in this study is summarized in Table 3.1. 
 
GENE  SEQUENCE 
Rat nkx2.5 fw: 5'-TATGAGCTGGAGCGGCGCTT-3' 
rev: 5'-TGGAACCAGATCTTGACCTG-3' 
Rat gata4 fw: 5'-AGGGTGCTGGGTTTCTTCAA-3' 
rev: 5'-GACAGTGTCTTGAAGCCTCG-3' 
Rat pkcε fw: 5'-CAAGCAGAAGACCAACAGTC-3' 
rev: 5'-CGAACTGGATGGTGCAGTTG-3' 
Rat pgk fw: 5'-TGTGGGCTCAGAAGTAGAGA-3' 
rev: 5'-TAGCTGGCTCAGCTTTAACC-3' 
Mouse myf5 fw 5’- TGAGGGAACAGGTGGAGAAC -3’ 
rev 5’-AGCTGGACACGGAGCTTTTA -3’ 
Mouse mrf4 fw 5’-GAGATTCTGCGGAGTGCCAT -3’ 
rev 5’-TTCTTGCTTGGGTTTGTAGC-3’ 
Mouse pkcε fw 5’- ATGTGTGCAATGGGCGCAAG -3’ 
rev 5’-CGAGAGATCGATGATCACGT -3’ 
Mouse hmga1 fw 5’-CAAGCAGCCTCCGGTGAG -3’ 
rev 5’- TGTGGTGACTTTCCGGGTCTTG -3' 
Mouse gusb fw 5’-CCGCTGAGAGTAATCGGAAAC- 3’  
rev 5’- TCTCGCAAAATAAAGGCCG -3’ 
 
Table 3.1 Primer sequences. 
 
 
3.4 Immunofluorescence  
BMMSCs were fixed with 4 % paraformaldehyde, permeabilized with 1 % BSA, 0.2 
% Triton X-100 and blocked in 10 % donkey serum. After 2 h of incubation at room 
temperature with anti-myosin heavy chain antibody (clone MF-20; Developmental Study 
Hybridoma Bank) or anti-connexin43 (CX43) (Santa Cruz Biotechnology, USA) diluted 1:200 
in 1 % donkey serum, cells were washed and incubated with Alexa Fluor 546 fluorescent anti-
mouse or anti-rabbit IgG for 1 h at room temperature. Nuclei were counterstained with DAPI. 
C2C12 were fixed with 4% paraformaldehyde in PBS for 10 minutes, permeabilized 3 
times with 1% BSA, 0.2% Triton X-100 in PBS for 5 minutes at room temperature and 
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incubated in 10% goat serum in PBS for 1 hour at room temperature to saturate non-specific 
binding sites. Samples were incubated for 1.5 hours with primary antibody diluted 1:200 in 
1% goat serum in PBS. PKC and myosin were detected by anti-PKC rabbit serum (Novus 
Biologicals, Littleton, CO NBP1-30126) and anti-myosin heavy chain antibody, respectively. 
Cells were washed in PBS and then incubated with secondary antibody (Alexa Fluor 488 
Donkey anti-mouse IgG and Alexa Fluor 594 anti-rabbit Donkey IgG) 1:1000 for 1 hour at 
room temperature. Nuclei were counterstained with DAPI.  
Fluorescence was viewed with a Nikon Eclipse 80i (Tokyo, Japan) fluorescent 
microscope equipped with Nikon Plan color 20X/0.50, Ph1 DLL, ∞/0.17, WD 2.1 and Nikon 
Plan color 40X/0.75, Ph2 DLL, ∞/0.17, WD 0,72 objectives and a camera (Nikon Camera DS-
JMC). Image acquisition were performed using Nis element F2.30 (Nikon, Japan). 
 
3.5 Cellular fractions separation and Western Blot 
analysis 
In cellular fractions separation experiments, 5x10
6 
cells were treated with NE-PER 
Nuclear and Cyotplasmic Extraction Reagents (Pierce), used according to manufacturer’s 
protocol. For Western Blot analysis, samples were resuspended in lysis buffer (50 mM Tris-
HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150 mM NaCl; 1 mM EDTA; 1 mM 
phenylmethylsulfonyl fluoride; 1 mM Na3VO4; 1 mM NaF). 30 μg of total proteins were 
loaded on 10% SDS-polyacrylamide gels and blotted onto nitrocellulose. Blots were incubated 
with the specific primary antibody (dilutions and buffers were as indicated by manufacturer) 
anti-Phospho-ERK1/2 (Cell Signaling, USA), anti-b-ACTIN (Sigma, Italy), anti-NKX2.5 
(abCam, UK) anti-GATA4 (abCam, UK) and anti-CONNEXIN43 (CX43) (sc-9059), anti-
PKC  (Merck Millipore, Darmstadt, Germany 06-991), anti-HSP70  (Sigma-Aldrich, St. 
Louis, MO, H5147), anti-insulin receptor β chain (IRβ, (Cell Signaling, Danvers, MA)#3025), 
anti-myogenin (Santa Cruz, Dallas, TE sc-12732), anti-myoD (Santa Cruz sc-32758), anti 
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GAPDH (Merk Millipore MAB374) anti-HMGA1 (Abcam, Cambridge, UK ab4078), washed 
and incubated with 1:5000 peroxidase-conjugated anti-rabbit or with 1:2000 peroxidase 
conjugated anti-mouse IgG (Pierce). Signals were revealed by ECL Supersignal West Pico 
Chemiluminescent Substrate detection system (Pierce). 
 
3.6 Cell transfection 
PKC expression levels were up-regulated by the transfection of murine GFP-PKC 
plasmid and GFP-K522M mutated PKC control plasmid (kindly provided by Prof. Peter 
Parker, Cancer Research Institute, UK) using the Superfect Transfection reagent (Qiagen, 
Hilden, Germany). Small interfering RNA (siRNA) silencing was obtained by transfection of 
400 nM specific siRNAs or control siRNA (Ambion, Austin, TX). PKC activity was also 
pharmacologically modulated by the V1-2 (CEAVSLKPT) and ψRACK (CHDAPIGYD) 
peptides, conjugated to TAT47-57 (CYGRKKRRQRRR) by a cysteine disulfide bound.  
Briefly, V1-2 is a specific PKC inhibitor that acts as a binding competitor between PKC 
and its anchoring protein RACK. Instead, ψRACK is a PKC allosteric activator, implicated 
in auto inhibitory intramolecular interactions. Peptides are highly specific for PKC and they 
don’t interact with other PKC isozymes. C2C12 cells and SC were incubated with DM and 
treated with 1µM of peptides every 24 hours for 48 or 72 hours.  
 
3.7 Short hairpin RNA (shRNA) cell infection 
PKC expression was also down-modulated by shRNA gene silencing using a 
pLKO.1 lentiviral vector encoding shRNA against mouse Pkc (Open-Biosystem, Thermo 
Scientific,Waltham, MA) and the MISSION pLKO.1-puro Non- Target shRNA Control 
Plasmid (Sigma-Aldrich, St. Louis, MO). The shRNA expressing viruses were produced in 
293TL cells according to standard protocols. Mouse proliferating C2C12 cell line was infected 
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with Pkcε shRNA or CTRL shRNA and then cultured in the presence of puromycin (2 μg/ml) 
to select infected, puromycin-resistant cells. 
 
 
3.8 Cardiotoxin injury and immunohistochemistry 
Acute skeletal muscle injury was induced by intramuscular injection of Cardiotoxin 
(10 μM) in the tibialis muscle of CD1 adult mice. In some exeriments, V1-2 or ψRACK 
(100 nM) were directly added to the cardiotoxin mix. To study the regenerative process, mice 
were euthanised for histological analysis 3 and 7 days after injury. Muscle samples were fixed 
with 4% paraformaldehyde and embedded in paraffin. Sections (4 µm) were blocked with goat 
serum and incubated with primary anti PKC antibody (Novus Biological NBP1-30126). 
Detection was performed using Vectastain elite ABC kit (Vector Laboratories) and nuclei 
were counterstained with haematoxylin. 
 
3.9 Statistical analysis 
All Panels show the mean values and Standard Deviations (SDs). p-values were 
calculated using the Anova - Dunnett test. 
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4.1 Role of PKCε in BMMSCs cardiac differentiation 
 
4.1.1 Characterization of BMMSCs and 5-azacytidine induction of 
cardiac differentiation  
 
 Bone marrow-derived mesenchymal stem cells (BMMSCs) are adult stem cells 
known to be able to differentiate in cardiomyocyte-like cells after 5-azacytidine treatment 
(Makino et al. 1999). In order to phenotypically and functionally characterize the BMMSCs 
used in these experiments, cells were isolated as extensively described in the Materials and 
Methods section. Cytofluorimetric analysis of surface markers CD14, CD34, CD44, CD45, 
CD90 and CD105 revealed a phenotypic profile consistent with that previously characterized 
in rat BMMSCs by Gao and colleagues (Gao et al. 2010). 
 
CD % CD % 
CD14 - CD44 90±3 
CD34 - CD90 87±2.7 
CD45 - CD95 92±1 
 
Table 4.1 Cytofluorimetric analysis of  BMMSCs surface markers  
 
To verify their ability to undergo osteogenic or adipogenic differentiation in vitro, BMMSCs 
were cultured with specific pro differentiation media. Cells stained with Alizarin Red show 
evident red precipitates formed by the reaction of this reagent with calcium crystals typically 
present in osteocytes (Fig. 4.1 a). Adipogenic differentiation was evaluated using the Oil Red 
Oil staining, that reacts with  lipid vacuoles, a typical structure of adipocytes (Fig. 4.1 b).  
 Finally, we proved the BMMSCs cardiac potential in vitro after 5-azacytidine 
treatment. The immunofluorescence analysis reveal the expression of cardiac markers like 
myosin heavy chain and Connexin43, an essential component of cardiomyocytes gap junction. 
(Fig. 4.1 c-h). The expression of Connexin43 was also confirmed by Western Blot analysis.
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Figure 4.1  
Panel A: Alizarin red staining of BMMSCs cultured in osteogenic inductive medium. Arrowhead highlights the red 
staining of calcium deposits. Panel B: Oil Red Oil staining of BMMSCs cultured in adipogenic inductive medium. 
Arrowhead highlights lipid vacuoles. Panel C-E: Myosin (MHC) immunofluorescence in control cells. Panel F-H: 
Myosin immunofluorescence in 5-Azacytidine treated cells. Panel I-K: Connexin43 (CX43) immunofluorescence in 
5-Azacytidine treated cells. Scale bar corresponds to 50μm. Panel L: Western Blot analysis of CX43 expression with 
(2, 7 and 22 days) or without 5-azacytidine. GAPDH was used as housekeeping protein. 
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4.1.2 PKCε expression during BMMSCs cardiac differentiation  
 In order to study the expression of  PKCε during 5-azacytidine induced - cardiac 
differentiation of BMMSC, mRNA levels of pkce, nkx2.5 and gata4 were analyzed by real-
time RT-PCR at days 1, 2, 3, 7 and 8 after treatment with 5-azacytidine.  (Fig. 4.2 a). The 
mRNA expression of PKCε is detectable in all samples analyzed but is maximal  at day 2 and 
it's down-modulated up to day 7, in which detection of PKCε was lowest. PKCε protein 
expression was analyzed by Western blot. Figure 4.2 b-c shows that the protein expression 
levels are consistent with the results obtained by Western Blot. Interestingly, we founded that 
the nkx2.5 and gata4 mRNA profiles are opposite to that of pkce (Fig. 4.2 a). Further studies 
were conducted to evaluate the possible implication of PKCε in nkx2.5 and gata4 expression 
during cardiac differentiation. 
 
 
Figure 4.2  
Panel A: Quantitative Real Time-PCR for pkce, nkx2.5 and gata4 mRNA expression in BMMSCs at different time 
points (1 day, 2 days, 3 days, 7 days and 8 days after treatment with 5-azacytidine). Housekeeping phosphoglycerate 
kinase 1 (pgk) gene was used as reference. Panel B: Western blot analysis of  PKCε expression at 1, 2 and 7 days 
after treatment with 5-azacytidine. Day 0 corresponds to the untreated sample. GAPDH was used as housekeeping 
protein. Panel C: densitometric analysis of PKCε protein expression. Values are means of 3 independent experiments 
± standard deviation. GAPDH was used for normalization. n=3; *p<0.05 Anova-Dunnet test (vs untreated cells). 
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4.1.3 PKCε role in nkx2.5 and gata4 expression during BMMSCs cardiac 
differentiation 
 
  
Figure 4.3  
Panel A: Quantitative Real Time-PCR for PKCε mRNA expression in BMMSC cultures transfected with wild type 
pkcε (PKCε-GFP), mutated pkcε (PKCεm-GFP), control siRNA (siCTRL) and specific pkcε siRNA (siPKCε) 
compared with untrasfected cells (-). n=3; *p<0,05 Anova-Dunnett test (vs untreated cells). Panel B: Quantitative 
Real Time-PCR for nkx2.5 and gata4 mRNAs in the cells transfected as explained in Panel A. Housekeeping  pgk was 
used as reference gene. Values are reported as means of 3 independent experiments ± standard deviation. Cell cultures 
were transfected 2 day after 5-axacytidine treatment and collected 24h later. n=3; *p<0,05 Anova-Dunnett test (vs 
untreated cells). 
 
 To test the role of PKCε in nkx2.5 and gata4 regulation, we both down-regulated and 
up-regulated PKCε expression in BMMSCs after 5-azacytidine treatment. Cells were 
engineered to express either a wild type mouse PKCε-GFP fusion protein (PKCε-GFP) or an 
inactive PKCε-GFP fusion protein carrying a point mutation in the catalytic core of the 
enzyme (PKCεm-GFP). The down-modulation was performed by using specific pkcε siRNA 
or control siRNA that has no known target in the mammalian genome. The analysis of gene 
expression was performed 2 days after 5-azacytidine treatment, when the PKCε protein level 
was maximum. mRNA expression of pkcε was analyzed to verify the efficiency of 
transfection (Fig. 4.3 a). Expression of PKCε-GFP significantly decreased the expression of 
both nkx2.5 and gata4 mRNAs, while specific pkcε siRNAs and the PKCεm-GFP plasmid 
induced the expression of these two cardiac markers of differentiation (Fig. 4.3 b). Taking 
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together, these data suggested that PKCε has a negative role in nkx2.5 and gata4 expression 
during BMMSCs cardiac differentiation. 
 
 
Figure 4.4  
Panel A: Western blot analysis of NKX2.5 and GATA4 in BMMSC cultures transfected with wild type pkcε (PKCε-
GFP), mutated pkcε (PKCεm-GFP), control siRNA (siCTRL) and specific pkcε siRNA (siPKCε) compared with 
untrasfected cells (-). TUBULIN was used for normalization. Panel B: densitometric analysis of NKX2.5 and 
GATA4 protein expression. Values are means of 3 independent experiments ± standard deviation. TUBULIN was 
used for normalization. n=3; *p<0.05 Anova-Dunnet test (vs untreated cells). 
 
 
4.1.4 PKCε modulates nkx2.5 and gata4 expression via ERK1/2 signaling 
pathway 
 To understand how PKCε is able to modulate nkx2.5 and gata4 expression during 
BMMSCs cardiac differentiation, we decided to study mitogen-activated protein kinases 
(MAPKs). Extracellular signal-regulated kinases 1/2 (ERK1/2) are known to be downstream 
of PKCε in a complex signaling pathway that regulate cell proliferation in several models 
(Basu and Sivaprasad 2007). ERK1/2 proteins are also expressed in cardiomyocytes, where 
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they are implicated in the regulation of calcium channel expression via nkx2.5 (Marni et al. 
2009). Western blot analysis of phospho-ERK1/2 , the active kinase form, showed that PKCε 
over-expression increases the phosphorilation of ERK1/2, while the siRNA - mediated down-
modulation has an opposite effect (Fig. 4.5 a-b). Interestingly, treatment of BMMSCs over-
expressing PKCε with the MEK1/2 inhibitor U0126 is able to rescue the expression levels of  
nkx2.5 and gata4 (Fig. 4.5c).  
 
 
 
Figure 4.5  
Panel A: Western blot analysis of phospho-ERK1/2 (pERK1/2) in BMMSC cultures transfected with wild type pkcε 
(3d pkcε), mutated pkcε (3d pkcε K522M), control siRNA (3d ctrl siRNAs) and specific pkcε siRNA (3d pkcε 
siRNAs) compared with untransfected cells (3d ctrl). β-ACTIN was used for normalization. Panel B: densitometric 
analysis of p-ERK1/2 protein expression. Values are means of 3 independent experiments ± standard deviation. β-
ACTIN was used for normalization. n=3; *p<0.05 Anova-Dunnet test (vs untreated cells). Panel C: Quantitative Real 
Time-PCR for nkx2.5 and gata4 mRNAs in controls (Ctrl), wild type pkcε (PKCε-GFP) transfected cells and mutated 
pkcε (PKCεm-GFP) transfected cells, treated with or without U0126. *p<0.05 Anova-Dunnet test (vs U0126 
untreated cells). 
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4.2 Role of PKCε in C2C12 and primary satellite cells 
skeletal muscle differentiation  
 
4.2.1 PKC expression is modulated during C2C12 and primary satellite 
cell differentiation. 
 
 Figure 4.6   
Panel A-B: PCR Real Time analysis of myf5, myogenin, mrf4 and pkcε during C2C12 cell differentiation. Panel C-D:  
PCR Real Time analysis of myoD, myogenin, mrf4 and pkcε during primary SC cultures differentiation. Panel E: 
Western Blot analysis of PKCε protein expression levels during C2C12 cell differentiation; HSP70 was used as a 
housekeeping protein. Panel F: densitometric analysis of PKCε protein levels. Results are representative of three 
independent experiments; values are reported as fold increase of control cell cultures (0 days) ± standard deviation. 
*p<0.05 Anova-Dunnett test (vs undifferentiated cells). 
 
To evaluate PKC expression during skeletal myotube formation in vitro and ex vivo, 
C2C12 and SC cells, respectively were cultured in Differentiation Medium (DM) for one week. 
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Quantitative real time PCR and Western Blot analyses of cells collected at several time points 
during differentiation show that both Pkc mRNA and protein levels were low in proliferating 
myoblasts but increased significantly during differentiation and subsequent myotube 
formation (Fig. 4.6 b, d, e, f). We also evaluated the expression of MRFs during 
differentiation and confirmed that expression of the early myogenic differentiation markers 
myod and myf5, progressively decreased during the differentiation of primary SC and C2C12 
cells, while myog and mrf4 accumulated during myofibers formation (Fig. 4.6 a-c). 
 
4.2.2 Cellular localization of PKCε and phospho-PKCε 
  
 To evaluate the subcellular localization of PKCε during the differentiation of C2C12 
cell cultures, we used different approaches.  
 First, immunofluorescence microscopy was applied. In undifferentiated C2C12 cells, 
PKCε levels were low but significantly increased after the induction of differentiation. PKCε 
preferentially localized to the nucleus (Fig 4.7a arrow heads) during the first 24 hours of 
skeletal muscle differentiation, however some cytoplasmic staining was observed at later time 
points (72 hours) (Fig. 4.7 a). The expression of the late muscle cell differentiation marker 
myosin was not detected in undifferentiated C2C12 cells, but progressively accumulated in the 
cytoplasm of forming myotubes.  
 Second, biochemical fractionation of C2C12 cells revealed that the nuclear content of 
both total and phosphorylated PKCε protein significantly increased 3 days after the induction 
of differentiation (Fig.4.7 b-c).  Phosphorilation of Ser729 is required for the kinase to achieve 
the mature conformation and it is a well-known marker of PKCε activation (Xu et al. 2007). 
We have also observed a concomitant down-regulation of HMGA1, a non-histone nuclear 
protein involved in the regulation of chromatin condensation and gene transcription and has 
also been implicated in preventing muscle cell differentiation (Brocher et al.. 2010). 
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Figure 4.7  
The subcellular localization of PKCε was studied by immunofluorescence and western blot analysis of protein 
expression in nuclear and cytoplasmic fractions of C2C12 undifferentiated (control) and differentiated cell cultures. 
Panel A: DAPI counterstaining of nuclei is shown in blue; PKCε staining shown as red fluorescence; myosin staining 
shown as green fluorescence. Arrow heads indicate cells with strong PKCε nuclear staining. Scale bar corresponds to 
10 μm. Panel B: Nuclear (n) and cytoplasmic (c) extracts from undifferentiated (control) and 72h differentiated 
C2C12 cells (72hs) were resolved by SDS-PAGE; membranes were probed with anti-PKCε, anti phospho-PKCε 
(pPKCε, Ser-729), anti-HMGA1, anti HSP70, and anti-myogenin antibodies. Anti-IR was used to exclude nuclear 
contamination by the cytoplasmic fraction. Panel C: Densitometric analysis of PKCε and phospho-PKCε expression 
levels. The values, normalized with respect to HSP70, are the mean of three independent experiments ± standard 
deviations (n=3). *p<0.05 Anova-Dunnett test (vs control cells). 
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4.2.3 PKCε up-regulation induces skeletal muscle differentiation via 
Myogenin and Mrf4 modulation 
 
 
Figure 4.8  
Panel A: Quantitative Real Time-PCR for PKCε mRNA expression in C2C12 cell cultures transfected with wild type 
pkcε (PKCε-GFP) or mutated pkcε (PKCεm-GFP) compared with untrasfected cells (-). n=3; *p<0,05 Anova-Dunnett 
test (vs untreated cells). Panel B: 
Quantitative Real Time-PCR for myogenin and mrf4 mRNA in C2C12 transfected with wild type pkcε (PKCε-GFP) or 
mutated pkcε (PKCεm-GFP). Housekeeping  gusb was used as reference gene. Values are reported as means of 3 
independent experiments ± standard deviation. Cell cultures were transfected and differentiated for 2 days. n=3; 
*p<0,05 Anova-Dunnett test of MRF4 expression (vs untreated cells ); #p<0,05 Anova-Dunnett test of Myogenin 
expression (vs untreated cells). Panel B a, b and c: Cell morphology was analyzed by bright-field observation.  
 
 To determine whether PKCε expression was correlated to myoblast differentiation 
and  MRFs induction in the in vitro C2C12 cell model, these cells were engineered to express 
either a wild type mouse PKCε -GFP fusion protein (PKCε -GFP) or an inactive PKCε -GFP 
fusion protein carrying a point mutation in the catalytic core of the enzyme (PKCεm-GFP). 
Two days after differentiation induction, cell morphology was analyzed by bright-field 
observation showing that the myotube numbers increased in PKCε-overexpressed cells, 
comparing with the inactive PKCε transfected cells (Figure 4.8 a, b , c). At the same time 
point, cells were collected and analyzed for myog and mrf4 expression by quantitative RT-
PCR. Expression of PKCε-GFP, but not the inactive mutated PKCεm-GFP, significantly 
increased myog and mrf4 mRNA expression (Fig. 4.8 A-B) with respect to untreated cells. 
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These results were confirmed using a pharmacological approach to modulate PKCε 
expression. C2C12 cells and primary SC cultures were treated with the ψεRACK PKCε specific 
activator displaying an increased myog and mrf4 mRNA expression, whereas the εV1-2 PKCε 
inhibitor yielded the opposite effect (Fig. 4.9).  
 
 
Figure 4.9  
Quantitative Real Time-PCR for myogenin and mrf4 mRNA in C2C12 (Panel A) and SC cultures (Panel B) treated 
with 1 μM of PKCε specific activator and inhibitor (ψεRACK and εV1-2 peptides, respectively). Housekeeping  gusb 
was used as reference gene. Values are reported as means of 3 independent experiments ± standard deviation. Cell 
cultures were transfected and differentiated for 2 or 3 days (Panel A and B, respectively). n=3; *p<0,05 Anova-
Dunnett test of Myogenin expression (vs untreated cells ); #p<0,05 Anova-Dunnett test of MRF4 expression (vs 
untreated cells). Cell morphology was analyzed by bright-field observation (Panel A a, b and c; Panel B d, e and f). 
 
 
4.2.4 PKCε down-modulates hmga1 during C2C12 cell differentiation. 
 
 Looking for a molecular target of PKCε signaling, we then analyzed the expression 
levels of HMGA1 during myogenic cell differentiation.  According to Brocher et al., we found 
a progressive decrease of HMGA1 expression (Fig. 4.10 a) in C2C12 cell cultures induced to 
terminal differentiation. To formally demonstrate that PKCε could remove HMGA1 
inhibition, allowing myoblasts to start the differentiation program, we then over-expressed 
PKCε in C2C12 cells growing in complete medium. Figures 4.10 b and c show that the rapid 
accumulation of PKCε in undifferentiated C2C12 cells promoted a parallel decrease of 
HMGA1 expression. At the same time Myogenin started to accumulate, notwithstanding the 
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persistence of mitogenic stimuli (10% of serum). To definitively prove the functional link 
between PKCε and HMGA1, we further performed double-transfection experiments with 
PKCε-specific shRNA and HMGA1-specific siRNA. Figure 4.10d shows that the sole down-
modulation of hmga1 crucially increases myog and Mrf4 transcription, as expected. On the 
contrary, pkcε silencing dramatically inhibited myog and mrf4 expression, blocking muscle 
differentiation. Of note, double silencing of Pkcε and Hmga1 induced the expression of 
muscle differentiation markers, indicating the functional necessity of Hmga1 down-regulation 
in the induction of the muscle cell differentiation program (Fig. 4.10 d). 
 
Figure 4.10  
Panel A: Western blot analysis of HMGA1 during C2C12 myogenic differentiation for 4 days. HSP70 was used for 
normalization. Panel B: Western blot analysis of HMGA1, Myogenin, PKCε and HSP70 in undifferentiated C2C12 
cell cultures treated with vectors expressing wild type PKCε (PKCε-GFP) or mutated PKCε (PKCεm-GFP). Panel C: 
densitometric analysis of HMGA1 and myogenin protein expression in C2C12 cells transfected with wild type or 
mutated PKCε. Values are means of 3 independent experiments ± standard deviation. HSP70 was used for 
normalization. n=3; *p<0.05 Anova-Dunnet test (vs untreated cells). Panel D: Quantitative Real Time-PCR for myog 
and mrf4 mRNA expression in C2C12 cell cultures infected with PKCε specific shRNA (shPKCε) or control shRNA 
(shCTRL). After selection of infected cells with puromycin (2μg/ml), cells were transfected with HMGA1 specific 
siRNAs (siHMGA1) or control siRNA (siCTRL) and then induced to muscle differentiation. Sample was collected at 
2 days of differentiation. n=3 *p<0,05 Anova-Dunnett test of mrf4 expression (vs control cell cultures ); #p<0,05 
Anova-Dunnett test of Myogenin expression (vs control cell cultures).  
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4.2.5 In vivo induction of PKCε during muscle regeneration 
 We studied the in vivo expression levels of PKCε during skeletal muscle regeneration 
experiments in cardiotoxin (CTX) treated mice. Figure 4.11a shows a spontaneous up-
regulation of PKCε expression in the damaged muscle starting from day 3 after the CTX 
injury. Morphological analysis shown in figure 4.11b confirms the expression of PKCε in 
most fibers of the injured region including the new regenerating fibers (centrally-nucleated 
fibers) (Fig. 4.11c).  
 To study the in vivo the effects of PKCε modulation on muscle regeneration, we first 
injected mouse tibialis muscle with CTX together with the PKCε inhibitor peptide (εV1-2) or 
the PKCε activator peptide (ψεRACK). Subsequently, protein levels of the myogenic factors 
MYOG and MYOD and PKCε phosphorylation levels (p-PKCε) were studied at 3 and 7 days 
after treatment. At day 3 we did not observe a difference in MYOG and MYOD expression 
(data not shown), while at day 7 both MYOG and MYOD decreased in muscles injected with 
PKCε inhibitor peptide, confirming the role of PKCε in in vivo muscle regeneration (Fig 4.11 
d-e). 
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Figure 4.11  
Panel A: Western blot analysis of protein extracts from regenerating tibialis muscle at 3 and 7 days after cardiotoxin 
induced injury in CD1 adult mice. The blot was incubated by anti-PKCε and anti-myogenin antibodies. HSP70 
confirmed equal loading samples. Panel B: Densitometric analysis of PKCε protein levels. Values, normalized by 
HSP70 expression levels, are mean of 3 independent experiments ± standard deviations. Panel C: 
Immunohistochemical detection of PKCε and haematoxilin/eosin (H/E) staining of serial muscle section of CD1 
untreated adult mice (control) and treated with CTX (3 and 7 days). Centro-nucleated regenerating fibers expressing 
PKCε are indicated (arrow heads). Scale bar  corresponds to 40 μm and it is the same for all panels. Panel D: p-
PKCε, Myogenin and MYOD western blot analysis of protein extracts from regenerating tibialis muscles at 7 days 
after cardiotoxin (CTX), cardiotoxin with εV1-2 (CTX εV1-2) and cardiotoxin with ψε RACK (CTX ψεRACK) 
injection. GAPDH was used as a loading control. Panel E: Densitometric analysis of p-PKCε, Myogenin and MyoD 
expression levels. The values, normalized with respect to GAPDH, are mean of 3 independent experiments ± standard 
deviations. *p<0,05 Anova-Dunnett test of PKCε expression vs untreated mucle; # p≤ 0,05 and § p≤0,03 Anova-
Dunnett-test.
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DISCUSSION 
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 The ε isoform of the novel group of PKC family is a serine-threonine kinase that has 
been implicated in many biological processes such as proliferation, differentiation, 
carcinogenesis and cell death (Newton and Messing, 2010).  PKCε is expressed in a wide 
variety of tissues and organs, including brain, skin, liver, adipose tissue, kidney, heart and 
skeletal muscle. We  and others have shown its role in the differentiation of hematopoietic 
(Gobbi et al., 2007; Mirandola et al., 2006; Gobbi et al., 2009) and intestinal (Gobbi et al., 
2012) cells, but to date very little information is available on its role in both cardiac and 
skeletal muscle differentiation.  
 
Role of PKCε in Bone Marrow Mesenchymal Stem Cells (BMMSCs) 
cardiac differentiation 
 The prevailing paradigm that the heart is a terminally differentiated organ and 
cardiomyocytes are all non-dividing cells is outdated. Also if the proliferative ability of adult 
cardiomyocytes is very low (Senyo et al. 2013), de novo cardiomyogenesis after injury was 
proved (Malliaras et al. 2013). However, little is known about the molecular mechanisms 
driving  cardiomyocyte or other stem cell sources to complete cardiomyogenic differentiation.  
 In the heart, PKCε was heavily characterized for its cardioprotective effects and its 
ability to mediate the preconditioning in ischemia-reperfusion injury. Its chemical activation 
before heart ischemia results in a strong cardioprotective effect (Inagaki et al. 2005), 
suggesting that it is needed in this process. Several mechanisms were proposed. The activation 
of PKCε induces the expression of mitochondrial Aldehyde Dehydrogenase 2 (ALD2), 
resulting in a cardioprotective effect on the damaged heart  (Dorn et al. 1999; Chen et al. 
2008). PKCε also increases sarcKATP channel activity after preconditioning (Aizawa et al. 
2004) and directly phosphorilates connexin43, a well known component of cardiomyocyte 
Gap junctions. (Doble et al., 2000; Bowling et al., 2001). 
 The current work has led to the identification of a new PKCε pathway implicated in 
the modulation of cardiac transcription factors nkx2.5 and gata4. We chose 5-azacytidine 
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treated - Bone Marrow Mesenchymal Stem Cells as in vitro model of cardiac differentiation 
(BMMSCs) (Makino et al.1999). The results show that PKCε has a peculiar kinetic of 
expression, with maximum expression occuring two days after 5-azacytidine induction of 
differentiation. This transient up-regulation of PKCε is followed by a strong down-modulation 
until day 7. Interestingly, both the cardiac transcription factors nkx2.5 and gata4 show similar 
expression profiles that are opposite to that of PKCε. This evidence supported the thesis that 
PKCε could be a negative modulator of nkx2.5 and gata4 transcription genes.  
 To better characterize this effect, we forced the modulation of PKCε by 
overexpressing vectors or with specific siRNAs. The results shown in this thesis demonstrate 
that the silencing of PKCε during the early phases of differentiation induced a significant 
increase of nkx2.5 and gata4. Opposite effects are shown when cells are transfected with an 
overexpressing vector. Surprisingly, cells expressing the K522M mutant form of PKCε - a 
mutation in the active site that prevents the ability of the kinase to phosphorilate its substrates- 
has a significant increase of nkx2.5 and gata4 expression, showing a dominant negative effect.  
 To understand the signaling pathway activated by PKCε during cardiac 
differentiation, we decided to study MAPK signaling and particularly the activation of 
ERK1/2 proteins. Previous studies have shown that PKCε is able to modulate cardiomyocyte 
proliferation and apoptosis via the ERK1/2 pathway (Basu and Sivaprasad 2007) and that the 
activation of ERK1/2 has a negative effect on nkx2.5 expression in cardiomyocyte cells 
(Marni et al. 2009). Experiments performed on cultures of 5-axacytidine - treated BMMSCs  
show that the activation of ERK1/2 is downstream of PKCε and that the abrogation of 
ERK1/2 phosphorilation, mediated by the chemical inhibitor U0126, significantly increases 
the expression of nkx2.5 and gata4, reverting the effect of PKCε up-regulation. 
Finally, the results reported in this thesis show that the expression of PKCε during cardiac 
differentiation have to be transient and finely regulated. In the early stage of cardiac 
differentiation PKCε has a negative role to regulate the expression of two essential cardiac 
transcription factors, nkx2.5 and gata4, via activation of the ERK1/2 signaling pathway. 
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Role of PKCε in skeletal muscle differentiation  
 During muscle development, a complex network of signaling pathways induces the 
myoblasts to fuse together and  form muscle fibers. After birth, postnatal muscle growth and 
regeneration is guaranteed by the resident stem cell called satellite cells.  Little is known about 
PKCs involvement in muscle cell differentiation. PKCθ is required for myoblast fusion, 
regulating FAK activation and, in turn, the expression of the pro-fusion genes caveolin-3 and 
β1D integrin (Madaro et al. 2011). Recently, Gaboardi et al. have shown that PKCε 
participates in insulin signaling, supporting muscle cell differentiation (Gaboardi et al. 2011). 
In the present investigation, we demonstrate that PKCε up-regulation during myogenic cell 
differentiation is required for late phase gene transcription and terminal differentiation. The 
C2C12 in vitro cell model helped us to understand the molecular pathway that links PKCε to 
the expression of myogenin, a key transcription factor of skeletal muscle differentiation. This 
function of PKCε involves the down-modulation of the chromatin binding protein HMGA1. 
The interplay between  PKCε  and HMGA1 was previously described to explain in part the 
ability of the active form of PKCε to repress the transcription of the insulin receptor, playing 
an important role in the induction of insulin resistance (Dey et al.2007). Our finding 
demonstrates that PKCε-HMGA1 axis activation also has an important implication also in 
skeletal muscle differentiation. The model proposed suggests that during differentiation PKCε 
expression and activation is up-regulated. The active form of the kinase, phosphorilated in the 
Ser 729 site, is able to translocate to the nucleus. Here, PKCε down- modulates the expression 
of HMGA1 and allows for the transcription of essential myogenic transcription factor such as 
Myogenin and Mrf4. Further studies will be needed to understand how PKCε modulates 
HMGA1 expression. Experiments conducted in other models suggest a direct interaction 
between these proteins and the ability of PKCε to directly phoshorilate HMGA1.    
 Finally, we studied the involvement of PKCε in a murine model of cardiotoxin - 
induced injury in muscle. We found that PKCε expression is up-modulated 7 days after injury 
and  it is localized preferentially in regenerating fibers. Pharmacological inhibition via  
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intramuscolar injection of a specific PKCε inhibitor peptide (εV1-2), led to a decrease of the 
active phospho-PKCε, Myogenin, and Myod expression suggesting a PKCε contribution to in 
vivo muscle regeneration. The PKCε activator peptide has no effects on PKCε 
phosphorylation and Myod and Myogenin expression induced by CTX, maybe because PKCε 
activation is phisiologically very high in the injured muscle.  
 
 Overall, by showing that PKCε is an upstream key regulator of skeletal muscle cell 
differentiation, we believe that it might represent an attractive model to be translated into 
human for further studies on satellite cell-driven muscle repair and substitution, with obvious 
clinically relevant implications in muscle pathology as atrophy, dystrophy and sarcopenia.   
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